 | |
 | |
| Clinical data | |
|---|---|
| Other names | ECYPLA; N-Ethyl-N-cyclopropyllysergamide; Lysergic acid ethylcyclopropylamide; LAEcP |
| Routes of administration | Oral |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H25N3O |
| Molar mass | 335.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).234 It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.3254 The drug has been encountered as a novel designer drug.4
Use and effects
EcPLA produces psychedelic effects in humans.4
Interactions
Pharmacology
Pharmacodynamics
EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does.3
The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.3
Pharmacokinetics
The in-vitro metabolism of EcPLA has been studied.6
Chemistry
Analogues
Analogues of EcPLA include MiPLA, LAMPA (MPLA), EPLA, EiPLA, ETFELA, and LSZ, among others.532
History
EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.3 It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.4
References
References
- "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". www.legifrance.gouv.fr (in French). 20 May 2021.
- Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Halberstadt AL, et al. (2020). "Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 12 (10): 1514–1521. doi:10.1002/dta.2911. ISSN 1942-7611. PMC 9191644. PMID 32803833.
- Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5117-z. PMC 6848745. PMID 30298278.
- "ECPLA". АИПСИН (in Russian). Retrieved 1 January 2026.
- Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID 39636448.
- Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, et al. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures" (PDF). Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. PMID 30617391. S2CID 58615418.